HCM
DGX icon

Highview Capital Management’s Quest Diagnostics DGX Stock Holding History

Highview Capital Management’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,501
Closed -$1.86M – 124
2026
Q1 		$1.86M Buy
9,501
+683
+8% +$133K 0.68% 39
2025
Q4 		$1.53M Buy
8,818
+2,613
+42% +$476K 0.54% 56
2025
Q3 		$1.18M Sell
6,205
-139
-2% -$24.7K 0.43% 66
2025
Q2 		$1.14M Buy
+6,344
New +$1.1M 0.44% 65

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Highview Capital Management's DGX Position: Q2 2026 in Review

Highview Capital Management sold out of Quest Diagnostics (DGX) in Q2 2026, closing a stake of 9,501 shares — an estimated $1.86M sold.

Highview Capital Management first reported a position in DGX in Q2 2025 and held it in 4 quarters. The position peaked at $1.86M in Q1 2026. 1,106 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Highview Capital Management reported no remaining Quest Diagnostics position as of Q2 2026 after selling out during the quarter.
  • Highview Capital Management sold 9,501 Quest Diagnostics shares in Q2 2026, an estimated $1.86M.
  • Highview Capital Management first reported a position in Quest Diagnostics in Q2 2025 and held it in 4 quarters.
  • Highview Capital Management's Quest Diagnostics position peaked at $1.86M in Q1 2026.
  • 1,106 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Highview Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.